Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Centessa Pharmaceuticals plc Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023",
"MULTIPLE PATHWAYS TO SIGNIFICANT VALUE CREATION"
08/01/2023 144 Form 144 - Report of proposed sale of securities:
07/10/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors Enrollment progressing toward interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of study"
07/03/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MULTIPLE PATHWAYS TO SIGNIFICANT VALUE CREATION"
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/24/2023 144 Form 144 - Report of proposed sale of securities:
05/23/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/15/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/15/2023 ARS Form ARS - Annual Report to Security Holders:
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 8-K Quarterly results
Docs: "Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 – Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline –"
05/01/2023 144 Form 144 - Report of proposed sale of securities:
04/03/2023 144 Form 144 - Report of proposed sale of securities:
03/30/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/30/2023 10-K Annual Report for the period ended December 31, 2022
03/30/2023 8-K Quarterly results
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/31/2023 SC 13G/A Medicxi Growth I LP reports a 21.1% stake in CENTESSA PHARMACEUTICALS PLC
01/27/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement, by and between the Company and SVB Securities LLC",
"Opinion of Goodwin Procter (UK) LLP"
01/27/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
01/26/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors LB101 is a conditionally tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody, being developed for solid tumors"
12/12/2022 8-K Investor presentation
Docs: "Ashley Road, Altrincham, Cheshire, United Kingdom, WA14 2DT,",
"Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension of Phase 2a Study of SerpinPC for Hemophilia"
11/23/2022 SC 13G EcoR1 Capital, LLC reports a 5.5% stake in Centessa Pharmaceuticals PLC
10/14/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/06/2022 8-K Quarterly results
09/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MULTIPLE PATHWAYS TO SIGNIFICANT VALUE CREATION"
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/10/2022 8-K Quarterly results
Docs: "Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022&#59; Provides Program Update for ZF874 –Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 –"
07/13/2022 EFFECT Form EFFECT - Notice of Effectiveness:
07/08/2022 8-K Quarterly results
07/01/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
07/01/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy